273 related articles for article (PubMed ID: 33895695)
21. Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Bao KK; Chan JC; Chan JG; Sutanto L; Cheung KM; Yiu HH
Breast; 2024 Feb; 73():103612. PubMed ID: 38007881
[TBL] [Abstract][Full Text] [Related]
22. Are We Prepared for the CDK4/6 Revolution With HR+/HER2- Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies.
Azoz S; Peters M; Jones G
Breast Cancer (Auckl); 2023; 17():11782234231215192. PubMed ID: 38034323
[No Abstract] [Full Text] [Related]
23. Corrigendum to "HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort" [Modern Pathology 36(4) 100087].
Baez-Navarro X; van Bockstal MR; Andrinopoulou ER; van Deurzen CHM
Mod Pathol; 2023 Dec; 36(12):100356. PubMed ID: 37951019
[No Abstract] [Full Text] [Related]
24. Evolution of HER2 Targeting in Metastatic Breast Cancer.
Bartsch R; Balic M
Breast Care (Basel); 2022 Dec; 17(6):521-523. PubMed ID: 36590142
[No Abstract] [Full Text] [Related]
25. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Mamounas EP; Untch M; Mano MS; Huang CS; Geyer CE; von Minckwitz G; Wolmark N; Pivot X; Kuemmel S; DiGiovanna MP; Kaufman B; Kunz G; Conlin AK; Alcedo JC; Kuehn T; Wapnir I; Fontana A; Hackmann J; Polikoff J; Saghatchian M; Brufsky A; Yang Y; Zimovjanova M; Boulet T; Liu H; Tesarowski D; Lam LH; Song C; Smitt M; Loibl S
Ann Oncol; 2021 Aug; 32(8):1005-1014. PubMed ID: 33932503
[TBL] [Abstract][Full Text] [Related]
27. Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors.
Li C; Li X
Onco Targets Ther; 2021; 14():2929-2939. PubMed ID: 33976551
[TBL] [Abstract][Full Text] [Related]
28. Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Moy B; Oliveira M; Saura C; Gradishar W; Kim SB; Brufsky A; Hurvitz SA; Ryvo L; Fagnani D; Kalmadi S; Silverman P; Delaloge S; Alarcon J; Kwong A; Lee KS; Ang PCS; Ow SGW; Chu SC; Bryce R; Keyvanjah K; Bebchuk J; Zhang B; Oestreicher N; Bose R; Chan N
Breast Cancer Res Treat; 2021 Jul; 188(2):449-458. PubMed ID: 33909203
[TBL] [Abstract][Full Text] [Related]
29. Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
Lin NU; Pegram M; Sahebjam S; Ibrahim N; Fung A; Cheng A; Nicholas A; Kirschbrown W; Kumthekar P
J Clin Oncol; 2021 Aug; 39(24):2667-2675. PubMed ID: 33945296
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors.
Raimondi L; Raimondi FM; Pietranera M; Di Rocco A; Di Benedetto L; Miele E; Lazzeroni R; Cimino G; Spinelli GP
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923563
[TBL] [Abstract][Full Text] [Related]
31. Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.
Badaoui S; Kichenadasse G; Rowland A; Sorich MJ; Hopkins AM
Oncologist; 2021 Jul; 26(7):562-568. PubMed ID: 33914991
[TBL] [Abstract][Full Text] [Related]
32. Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
Int J Cancer; 2021 Apr; ():. PubMed ID: 33905134
[TBL] [Abstract][Full Text] [Related]
33. [Consensus recommendations for the clinical application of CDK4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer].
;
Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):405-413. PubMed ID: 33902203
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers.
Sibert NT; Wesselmann S; Breidenbach C; Blohmer J; Brückner B; Gebauer G; Dos Santos Guilherme M; Hartkopf A; Lindner C; Peschel S; Rieger L; Schad F; Strecker P; Ferencz J; Dieng S; Inwald EC; Kowalski C; Ortmann O
J Cancer Res Clin Oncol; 2022 Mar; 148(3):719-726. PubMed ID: 33914125
[TBL] [Abstract][Full Text] [Related]
36. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A; van Ramshorst MS; van Werkhoven ED; Mandjes IA; Kemper I; Vulink AJ; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS
JAMA Oncol; 2021 Jul; 7(7):978-984. PubMed ID: 34014249
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.
Carausu M; Carton M; Darlix A; Pasquier D; Leheurteur M; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Verret B; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lefeuvre-Plesse C; Petit T; Uwer L; Jouannaud C; Larrouquere L; Chevrot M; Courtinard C; Cabel L
ESMO Open; 2021 Jun; 6(3):100150. PubMed ID: 33984675
[TBL] [Abstract][Full Text] [Related]
38. Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer.
Ring A; Battisti NML; Reed MWR; Herbert E; Morgan JL; Bradburn M; Walters SJ; Collins KA; Ward SE; Holmes GR; Burton M; Lifford K; Edwards A; Robinson TG; Martin C; Chater T; Pemberton KJ; Brennan A; Cheung KL; Todd A; Audisio RA; Wright J; Simcock R; Green T; Revell D; Gath J; Horgan K; Holcombe C; Winter MC; Naik J; Parmeshwar R; Gosney MA; Hatton MQ; Thompson AM; Wyld L;
Br J Cancer; 2021 Jul; 125(2):209-219. PubMed ID: 33972747
[TBL] [Abstract][Full Text] [Related]
39. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
Goyal RK; Jain P; Nagar SP; Le H; Kabadi SM; Davis K; Kaye JA; Du XL; Wang M
Leuk Lymphoma; 2021 Jun; 62(6):1325-1334. PubMed ID: 33966583
[TBL] [Abstract][Full Text] [Related]
40. Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.
Du F; Yuan P
JAMA; 2021 May; 325(17):1791-1792. PubMed ID: 33944881
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
